High‐dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial

[1]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[2]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[3]  H. Gylling,et al.  Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment , 2003, European journal of clinical investigation.

[4]  L. Teichholz.  Statin-associated myopathy with normal creatine kinase levels. , 2003, Annals of internal medicine.

[5]  A. Awad,et al.  Effect of phytosterols on cholesterol metabolism and MAP kinase in MDA-MB-231 human breast cancer cells. , 2003, The Journal of nutritional biochemistry.

[6]  T. Bayer,et al.  Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain DOI 10.1194/jlr.M200071-JLR200 , 2002, Journal of Lipid Research.

[7]  U. Beisiegel,et al.  Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. , 2002, Archives of neurology.

[8]  Marc Evans,et al.  Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle , 2002, Drug safety.

[9]  P. M. Yao,et al.  Free Cholesterol Loading of Macrophages Is Associated with Widespread Mitochondrial Dysfunction and Activation of the Mitochondrial Apoptosis Pathway* , 2001, The Journal of Biological Chemistry.

[10]  Guillaume Sebire,et al.  Blue Native Polyacrylamide Gel Electrophoresis: A Powerful Tool in Diagnosis of Oxidative Phosphorylation Defects , 2001, Pediatric Research.

[11]  G. Tint,et al.  Macrophage 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in sitosterolemia: effects of increased cellular cholesterol and sitosterol concentrations. , 2001, Metabolism: clinical and experimental.

[12]  A. Smith,et al.  Plant sterols regulate rat vascular smooth muscle cell growth and prostacyclin release in culture. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.

[13]  A. Olsson.  Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin. , 2001, The American journal of cardiology.

[14]  R. Davidson,et al.  Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 2001, The American journal of cardiology.

[15]  K. Boberg,et al.  Inborn errors in bile acid biosynthesis and storage of sterols other than cholesterol , 2001 .

[16]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[17]  M. Mercuri,et al.  Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. , 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[18]  P. M. Yao,et al.  Free Cholesterol Loading of Macrophages Induces Apoptosis Involving the Fas Pathway* , 2000, The Journal of Biological Chemistry.

[19]  T. Mjörndal,et al.  HMG-CoA Reductase Inhibitors and Myotoxicity , 2000, Drug safety.

[20]  M. Mercuri,et al.  Lipid‐Altering Efficacy and Safety of Simvastatin 80 mg/Day: Long‐Term Experience in a Large Group of Patients with Hypercholesterolemia , 2000, Clinical cardiology.

[21]  M. Mercuri,et al.  Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. , 1999, The American journal of cardiology.

[22]  A. Honda,et al.  Down-regulation of cholesterol biosynthesis in sitosterolemia: diminished activities of acetoacetyl-CoA thiolase, 3-hydroxy-3-methylglutaryl-CoA synthase, reductase, squalene synthase, and 7-dehydrocholesterol delta7-reductase in liver and mononuclear leukocytes. , 1998, Journal of lipid research.

[23]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[24]  Y. Chen,et al.  beta-Sitosterol inhibits HT-29 human colon cancer cell growth and alters membrane lipids. , 1996, Anticancer research.

[25]  R. Laaksonen,et al.  The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. , 1996, The American journal of cardiology.

[26]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[27]  R. Laaksonen,et al.  Serum and muscle tissue ubiquinone levels in healthy subjects. , 1995, The Journal of laboratory and clinical medicine.

[28]  R. Laaksonen,et al.  Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short‐term simvastatin treatment in humans , 1995, Clinical pharmacology and therapeutics.

[29]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[30]  T. Bourgeron,et al.  Biochemical and molecular investigations in respiratory chain deficiencies. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[31]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[32]  R. Tilvis,et al.  Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. , 1990, American journal of epidemiology.

[33]  I. M. Shepherd,et al.  Fatal Lactic Acidosis in Infancy with a Defect of Complex III of the Respiratory Chain , 1989, Pediatric Research.

[34]  H. Kempen,et al.  Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. , 1988, Journal of lipid research.

[35]  S. Dimauro,et al.  Cytochrome c oxidase deficiency in leigh syndrome , 1987, Annals of neurology.

[36]  K. Einarsson,et al.  Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. , 1987, Journal of lipid research.

[37]  M. Brown,et al.  Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. , 1980, Journal of lipid research.

[38]  M. Danson,et al.  Citrate synthase. , 2020, Current topics in cellular regulation.

[39]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[40]  L. Ernster,et al.  AN ELECTRON-TRANSPORT SYSTEM ASSOCIATED WITH THE OUTER MEMBRANE OF LIVER MITOCHONDRIA , 1967, The Journal of cell biology.

[41]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.